79 Results
Sort By:
Published on October 20, 2022
McGill University is launching the Victor Phillip Dahdaleh Institute of Genomic Medicine with gifts totaling more than $30 million from the owner and chairman of Dadco, a privately owned investment, manufacturing, and trading group. “Dahdaleh’s generous gift provides crucial resources to help us attract impactful young scientists, students and trainees from…
Published on October 14, 2022
With COVID-19 on the scene, talk of other respiratory viruses has taken a backseat. But this doesn’t change the fact that they are as present as ever, lurking in the background. Influenza is one such virus, causing an estimated 1 billion cases globally every year—of these, upwards of 500,000 end…
Published on October 14, 2022
Sponsored content brought to you by Strata Oncology CEO and co-founder Dan Rhodes, PhD, describes how molecular testing of tumors as it exists today is insufficient to realize the full promise of precision cancer care, and how Strata has developed a new category of tests that provides comprehensive treatment selection…
Published on September 15, 2022
Kevin KeeganVP and General Manager, OncologyIllumina Phil Febbo, MDChief Medical OfficerIllumina David Bartlett, MDChairAllegheny Health Network (AHN) Cancer Institute Sandip Patel, MDAssociate Professor of MedicineUniversity of California, San Diego Rachel Sanborn, MDMedical OncologistEarle A. Chiles Research InstituteProvidence Cancer Institute Broadcast Date: September 20, 2022Time: 8:00 am PT, 11:00 am ET, 17:00 CET…
Published on August 16, 2022
By Scott Tomlins, MD, PhD, Co-Founder & Chief Medical Officer, Strata Oncology Sponsored content brought to you by ADCs are part of the expression-based therapy revolution in cancer treatment Oncology is seeing accelerated development of new expression-based therapy classes with the potential to deliver unprecedented improvements in patient outcomes.…
Published on June 29, 2022
A compound derived from the bark of the Brazilian lapacho tree has been modified by researchers into a potential therapeutic compound for the treatment of acute myeloid leukemia (AML). Beta-lapachone, a naturally occurring member of the cytotoxic ortho-quinone family of compounds, failed clinical trials back in the 1960s due to…
Published on March 4, 2022
Broadcast Date: March 29, 2022Time: 8:00 am PT, 11:00 am ET, 16:00 CET REGISTER NOW Despite many advances in cancer treatments, therapy response rates are not high enough – ranging from 20%-60% depending on the type of cancer. This reality is driven by the fact that cancer is a heterogeneous disease, yet…
Published on October 19, 2021
After completing $121 million in Series C financing last year, Sema4 pondered how much more capital it would need—and the best way to raise it—in order to offer more of the holistic precision medicine solutions on which it had begun to gain traction from health systems. Sema4 harnesses 21st century…
Published on September 13, 2021
Oxford Nanopore, the pioneer developer of DNA/RNA nanopore sensing tools that include its pocket-sized MinION DNA/RNA sequencer, has disclosed plans for an initial public offering that could value the company at a reported £4 billion ($5.5 billion). Oxford Nanopore seeks to trade its shares on the London Stock Exchange. “Ever…
Published on December 15, 2020
REGISTER NOW Broadcast Date: February 9, 2021Time: 8:00 am PT, 11:00 am ET, 17:00 CET The number of targeted therapies and the complexity of biomarker detection linked to these therapies has grown over the last decade. To accommodate it, the drug development process must also evolve. In this Clinical OMICs…
Published on June 24, 2020
Thermo Fisher Scientific announced on Tuesday that it will expand the scope of it work with pharma Daiichi Sankyo via a new co-development agreement for a companion diagnostic (CDx) designed to identify non-small cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) mutations who may be…
Published on June 17, 2020
Royal Philips and the Texas MD Anderson Cancer Center announced yesterday a collaboration that will provide oncologists world-wide with evidence-based cancer therapy recommendations and clinical trials information based on a patient’s genomic profile via Philips’ oncology informatics platform tied into the Precision Oncology Decision Support (PODS) system at MD Anderson.…
Published on February 20, 2020
The first cell atlas of the human thymus gland has been mapped using scRNA-seq and it could lead to new immune therapies to treat cancer and autoimmune disease. The thymus makes T cells, and these are currently being used to treat B-cell lymphoma and leukemia. CAR-T—chimeric antigen receptor T-cell—therapy is…
Published on October 21, 2019
Researchers at the Karolinska Institutet in Sweden say they have developed a new cheap method that can identify highly heterogeneous tumors that tend to be aggressive, and therefore need to be treated more aggressively. The technique is presented in an article (“CUTseq is a versatile method for preparing multiplexed DNA…
Published on September 5, 2019
REGISTER NOW Broadcast Date: October 1, 2019Time: 8:00 am PT, 11:00 am ET, 17:00 CET Accurate monitoring of cell signaling pathway proteins, particularly tyrosine phosphorylation (pTyr) on these proteins, has proven challenging due to the low cellular abundance of these targets and lack of standardized targeted proteomic methodologies and reagents.…